<DOC>
	<DOCNO>NCT01279720</DOCNO>
	<brief_summary>Adenosine deaminase deficiency inherit disorder result severe abnormality immune system leave child unable fight infection . This trial aim treat adenosine deaminase deficiency patient use gene therapy .</brief_summary>
	<brief_title>Gene Therapy ADA Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>1 . Patients lack human leukocyte antigen ( HLA ) genotypically identical bone marrow donor OR phenotypically match family unrelated donor AND show incomplete immune reconstitution Polyethylene glycolmodified adenosine deaminase ( PEGADA ) enzyme replacement therapy ( define absolute CD4+ count &lt; 300 cell/mm3 remain immunoglobulin replacement therapy ) 2 . Diagnosis ADASCID ( Severe combine immunodeficiency ( SCID ) due adenosine deaminase ( ADA ) confirm DNA sequencing OR confirm absence &lt; 3 % ADA enzymatic activity peripheral blood ( neonate ) umbilical cord blood erythrocytes and/or leukocyte culture fetal cell derive either chorionic villus biopsy amniocentesis , prior institution PEGADA replacement therapy 3 . Parental/guardian/patient sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Adenosine deaminase deficiency</keyword>
	<keyword>Gene therapy</keyword>
</DOC>